Skip to main content
Indian stocks: Visit www.stage2stocks.com →

Qiagen N.V.

Stage 2 · Advancing · week 6

As of Oct 22, 2026, Qiagen is in Stage 2, the uptrend phase, now in week 6 (since Sep 16, 2026). It closed at $50.22, 9.0% below its 52-week high and above its 200-day average, which is rising.

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. More about the company

$50.22
+0.44% today
$10.4B · Large cap
Market Neutral — Building

Pro read

Pro

Our read

Early entry: still early enough in its move

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 32 in Diagnostics & Research · #1 of 272 in Health Care

Is QGEN early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 16w
S2 14w
S4 15w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 1w → S4 16w → S1 7w → S2 8w → S3 10w → S2 5w → S3 3w → S2 10w → S3 4w → S4 5w → S1 1w → S2 7w → S3 1w → S4 10w → S1 5w → S2 14w → S3 12w → S2 2w → S3 2w → S4 1w → S3 1w → S2 8w → S3 2w → S4 15w → S1 9w → S2 5w current
Total tracked: 164 weeks across 26 stage runs.

QGEN among Diagnostics & Research27th of 44 by relative strength

All 44 →
Stocks in Diagnostics & Research ranked by relative strength, with stage and one-month change
#StockStageRS1M
1CDNAStage 2 · wk 2499+27.3%
2BDSXStage 2 · wk 1898−18.3%
3ILMNStage 2 · wk 2497+5.5%
4GHStage 2 · wk 2197−7.6%
5NTRAStage 2 · wk 2096+2.7%
6CRLStage 2 · wk 1692+22.5%
7RVTYStage 2 · wk 1890+10.7%
8PSNLStage 2 · wk 1790−3.2%
…27QGENStage 2 · wk 658+14.9%
vs 52W High
-9.0%
$32.34 lo$55.16 hi
9.0% below 52W high, pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 6
1w13w26w
Week 6, early Stage 2
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
18.8%
200 DMA: $42.28 · rising
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
14.64x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↑
Short-term trend rising strongly
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+14.9%
3M
+21.4%
6M
+33.5%
YTD
+12.1%
1Y
+4.4%
Scan Membership
Breakout Watch
Latest: 2025-06-16
12 appearances in last 60 days. First seen: 2019-03-04.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 6 · Vol 14.64x
2026-10-21S2
Wk 6 · Vol 4.79x
2026-10-20S2
Wk 5 · Vol 4.10x
2026-10-19S2
Wk 5 · Vol 0.86x
2026-10-16S2
Wk 5 · Vol 0.78x
2026-10-15S2
Wk 5 · Vol 0.51x
2026-10-14S2
Wk 5 · Vol 0.63x
2026-10-13S2
Wk 4 · Vol 0.55x
2026-10-12S2
Wk 4 · Vol 0.45x
2026-10-09S2
Wk 4 · Vol 0.47x
2026-10-08S2
Wk 4 · Vol 0.59x
2026-10-07S2
Wk 4 · Vol 0.98x
Moving averages & range
50 DMA
$44.28
200 DMA
$42.28
52W High
$55.16
52W Low
$32.34
5D Low
$46.13
Resistance levels (recent highs)
20d High
$50.22
60d High
$50.22
120d High
$50.22
250d High
$55.16
Next resistance
+9.8%
to 250d High
P/E (TTM)
25.5
Forward 19.2
Earnings Growth (YoY)
+7.9%
Revenue +0.3%
ROE
+11.9%
Profit margin +19.5%
Dividend Yield
0.70%
P/B 3.1

Qiagen: quick answers

What stage is Qiagen in?

As of Oct 22, 2026, Qiagen (QGEN) is in Stage 2, the uptrend phase. It entered Stage 2 on Sep 16, 2026 and is in week 6. What the four stages mean

Is Qiagen in an uptrend?

Yes. Qiagen is in a Stage 2 uptrend. It trades 18.8% above its 200-day average, which is rising.

How far is Qiagen from its 52-week high?

Qiagen closed at $50.22 on Oct 22, 2026, 9.0% below its 52-week high of $55.16. Its 52-week low is $32.34.

How has Qiagen performed over the past year?

As of Oct 22, 2026, Qiagen is up 4.4% over the past year and up 12.1% so far in 2026.

Which sector and industry is Qiagen in?

Qiagen is in the Diagnostics & Research industry, part of the Health Care sector.

About this companyHealth Care· Diagnostics & Research

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.